Regression discontinuity analysis of Gavi’s impact on vaccination rates

Journal of Development Economics
Volume 140 Pages 1-374 (September 2019)


Research article Abstract only
Regression discontinuity analysis of Gavi’s impact on vaccination rates
Sarah Dykstra, Amanda Glassman, Charles Kenny, Justin Sandefur
Pages 12-25
Since 2001, an aid consortium known as Gavi has accounted for over half of vaccines purchased in the 75 eligible countries with an initial GNI below $1,000 per capita. Regression discontinuity estimates suggest most aid for cheap, existing vaccines like hepatitis B and DPT was inframarginal: for instance, hepatitis B doses sufficient to vaccinate roughly 75% of infants raised vaccination rates by single-digit margins. These results are driven by middle-income countries near the eligibility threshold, and do not preclude larger gains for the poorest countries, global externalities via vaccine markets, or impacts on newer vaccines such as pneumococcal or rotavirus for which income eligibility rules were relaxed.